NCT02649387View on ClinicalTrials.gov

Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 8, 2016

Primary Completion Date

December 14, 2023

Study Completion Date

January 15, 2026

Conditions
Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic Leukemia
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT02649387 - Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy | Biotech Hunter | Biotech Hunter